23 a 25 de maio de 2019 • 
Maksoud Plaza Hotel • São Paulo - SP
ERA 2019


Haner Direskeneli

Haner Direskeneli

Haner Direskeneli, MD is a Professor of Rheumatology and is currently the Chief of the Division of Rheumatology and Department of Internal Medicine in Marmara University, School of Medicine, Istanbul, Turkey.
He graduated from Istanbul University, had residency trainings in Internal Medicine/ Rheumatology in Marmara University and fellowships in Lupus Research Unit (1992) and Department of Oral Immunology in UMDS, London UK (1992-1993). He is a member of Turkish Rheumatology Society, American College of Rheumatology (ACR), Turkish Immunology Society and International Society for Behcet’s disease (ISBD).
His current main research interests are infectious etiology, oral health, immune response/genetics, imaging and assessment in ‘Behcet’s Disease’ and immune response/genetics, assessment (imaging, outcome tools) and management of ‘Takayasu’s arteritis”. He is a member of OMERACT large-vessel vasculitis and Behcet’s Study Interest Groups and is part of a EULAR taskforce for Imaging in large-vessel vasculitis. He has collaborations with Michigan University, Mayo Clinic and Vasculitis Clinical Research Consortium (VCRC) in USA, Leeds University in UK, Paris and Ottawa Universities. He has >250 peer-reviewed articles with > 6000 citations.

Xenofon Baraliakos

Xenofon Baraliakos, MD, PhD

Dr Xenofon Baraliakos is a Senior Consultant and scientific coordinator at the Rheumazentrum Ruhrgebiet Herne and Associate Professor for Internal Medicine and Rheumatology at the Ruhr-University Bochum, Germany.
He studied Human Medicine at the universities of Magdeburg and Berlin, Germany and went on to receive a PhD degree in 2005 with a thesis entitled ‘MRI examinations of the spine in patients with ankylosing spondylitis before and after therapy with the monoclonal anti-TNF-α antibody infliximab’.
Dr. Baraliakos received his official Board Degrees in orthopaedic surgery in 2007 and in Internal Medicine and Rheumatology in 2014. His research interests include clinical and academic research in the field of spondyloarthritides, with special emphasis on imaging outcomes and treatment of the disease.
Among others, Dr Baraliakos won the EWRR Award, in 2005, the EULAR Young Investigator Award, in 2006 and 2008, the German patient’s AS Society Award in 2010 and the 2014 Award for Excellence in Clinical Research from the European Society for Clinical Investigations.
Dr Baraliakos is the current Chair of the EULAR standing committee for musculoskeletal imaging and member of the EULAR Executive Committee. He is also the current secretary and President-elect of ASAS (Assessment of Spondyloarthritis International Society). He holds membership of the American College of Rheumatology (ACR), the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the German Society of Rheumatology. Finally, he also acts as a reviewer and is an Associate Editor in a number of major rheumatological journals.

Riekie Alten

Riekie Alten

(Universidade de Medicina de Berlim)

Professor of Medicine, Head of Department of Internal Medicine and Rheumatology, Clinical Immunology and Osteology at Schlosspark-Klinik, University Medicine Berlin, where she also serves as the director of the Rheumatology Research Center.
She received her medical degrees from the Free University Berlin and after graduating, she pursued immunology research at the Institute of Immunology, University of Zürich, Switzerland.
Prof. Dr. Alten conducted her training in internal medicine at the Free University Berlin, and this was followed by training in Rheumatology in Zürich. She has received board certification in internal medicine (1984), rheumatology (1985), physical therapy and rehabilitation medicine (1998), and sports medicine (2001). Since 1990, she has been head of the Department of Internal Medicine, Rheumatology at Schlosspark-Klinik, University Medicine Berlin.
Prof. Dr. Alten’s research interests focus on the development and systematic evaluation of biological and immunolomodulatory treatments for the rheumatic diseases.
She has been lead and principle investigator in clinical trials of novel therapies in rheumatic diseases and has contributed to several investigator-initiated trials. She has also published more than 200 original papers, book chapters and reviews.
Prof. Dr. Alten is a member of the OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. She has served as board member of German Medical Association, as member of the Institute for Approval of drugs for the German Ministry of Health, as board member of the “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.


Sociedade Paulista de Reumatologia


Novartis Pfizer Lilly
Abbvie Janssen
Roche UCB Bristol
GSK Libbs Zodiac